Orchestra Life Sciences Expands into Europe to Support Radiopharmaceutical Execution

Appoints Vinod Ramnandanlal as President and Managing Director of European Operations

Jan. 27, 2026 at 9:17am

Got story updates? Submit your updates here. ›

Orchestra Life Sciences, a technical consultancy providing strategic support and scientific expertise for advanced pharmaceutical therapies, has announced the expansion of its European presence to strengthen the company's ability to support advanced therapy and radiopharmaceutical programs operating across global markets. The expansion reflects growing demand for integrated execution, infrastructure readiness, and manufacturing strategy as advanced therapies scale internationally. To lead the expansion, Orchestra has appointed Vinod Ramnandanlal as President and Managing Director of Orchestra Life Sciences Europe.

Why it matters

Europe plays a critical role in the global advanced therapy ecosystem, particularly in radiopharmaceutical manufacturing, automation, and containment technologies. As more development and commercialization programs span North American and European operations, Orchestra's expanded presence is designed to enable closer collaboration, earlier engagement, and more coordinated delivery across regions.

The details

Through its European expansion, Orchestra will support clients with advanced therapy and radiopharmaceutical manufacturing strategy, infrastructure and facility readiness planning, and cross-regional execution and partner coordination. The company's approach focuses on early, informed decision-making to reduce downstream risk and support reliable translation from development to patient access.

  • Orchestra Life Sciences announced the expansion on January 27, 2026.

The players

Orchestra Life Sciences

A technical consultancy providing strategic support and scientific expertise to advance pharmaceutical therapies for cancer and rare diseases.

Vinod Ramnandanlal

The newly appointed President and Managing Director of Orchestra Life Sciences Europe, bringing deep leadership experience across nuclear medicine, radiopharmaceutical infrastructure, and complex energy systems.

Got photos? Submit your photos here. ›

What they’re saying

“Orchestra has been supporting clients engaged in the European radiopharmaceutical market for some time, and we continue to see strong momentum across the region. As programs scale and become increasingly global, we want to be able to better support our clients on the ground. We are excited to establish our presence in Europe and to do so with Vinod's deep experience in nuclear medicine and complex program execution.”

— Emilie Pelletier, CEO & Co-Founder of Orchestra Life Sciences (PRNewswire)

“Europe is where many radiopharma programs are shaped early by financing, research, infrastructure, and isotope availability. Establishing a European presence allows Orchestra to engage upstream, helping developers navigate facility readiness and execution tradeoffs before those constraints become risks to patients or programs.”

— Vinod Ramnandanlal, President and Managing Director of Orchestra Life Sciences Europe (PRNewswire)

The takeaway

Orchestra Life Sciences' expansion into Europe strengthens the company's ability to support advanced therapy and radiopharmaceutical programs operating across global markets, reflecting the critical role Europe plays in the advanced therapy ecosystem and the growing demand for integrated execution, infrastructure readiness, and manufacturing strategy as these therapies scale internationally.